Compare CarMax, Inc (KMX) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs McKesson Corporation — how do they compare? CarMax, Inc trades at $52.61 (market cap $7.64B), while McKesson Corporation trades at $938.84 (market cap $108.46B). The key difference: McKesson Corporation is far larger — about 14.2× CarMax, Inc's market cap, and McKesson Corporation pays a 0.4% dividend while CarMax, Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and McKesson Corporation for 74 Days on average.
| KMX | MCK | |
|---|---|---|
Market Cap | $7.64B | $108.46B |
Volume | 3,610,116 | 712,607 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $995.69 |
52-Week Low | $30.88 | $725.17 |
Typical Hold Time | 49 Days | 74 Days |
Enterprise Value | $25.34B | $115.00B |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $53.79, up 0.96% with recent earnings beats driving positive momentum. The stock shows bearish technical signals but strong fundamental improvements with Q2 2026 EPS of $1.16 beating estimates by 58%. Revenue grew 19.5% to $7.9 billion in the latest quarter, while the company's Shift into GEAR strategy shows early success. Valuation metrics remain reasonable with P/E of 25.37 and P/S of 0.28, though net margins remain thin at 1.06%.
KMX presents a turnaround story with improving operational execution but faces margin pressure and high debt levels. The consensus price target of $58.89 suggests 9.5% upside potential, though analyst sentiment remains cautious with 62% hold ratings. Key risks include used car market volatility and interest rate sensitivity, while catalysts include continued execution of the growth strategy and potential share buybacks.
McKesson (MCK) trades at $930.25, up 2.19% today, with a bullish technical outlook and strong analyst support. The stock shows consistent earnings beats, with Q2 2026 EPS of $9.93 surpassing the $9.56 estimate. Revenue growth is robust, reaching $359.05B in 2025, though net margins are thin at 1.12%. Recent news highlights a key distribution extension with CVS Health through 2032, reinforcing long-term visibility.
The outlook is positive, driven by operational strength and strategic partnerships, but investors face risks from margin pressure and drug pricing uncertainty. With 81% of analysts rating it Buy and a consensus target of $956.43, the stock offers upside, though high RSI levels suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
